Should we switch MDD patient from SSRI to SNRI if they are experiencing sexual dysfunction?
Incidence of sexual dysfunction across 12 antidepressants
DSM-5, The Diagnostic and Statistic Manual of Mental Disorders, Fifth Edition; MDD, Major depressive disorder.
Florido et al. ECNP 2019, Poster P.023.
Sexual dysfunction is a common side effect of antidepressants, particularly with selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs).1,2 In the instance where a patient is suffering from SSRI-induced sexual dysfunction, switching to an antidepressant of another class that is associated with fewer sexual side effects and improved treatment adherence may be a viable option.
Brintellix®(vortioxetine) improved sexual dysfunction in most dimensions and phases unlike other antidepressants
DSM-5, The Diagnostic and Statistic Manual of Mental Disorders, Fifth Edition; MDD, Major depressive disorder.
Florido et al. ECNP 2019, Poster P.023.
Sexual dysfunction is a common side effect of antidepressants, particularly with selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs).1,2 In the instance where a patient is suffering from SSRI-induced sexual dysfunction, switching to an antidepressant of another class that is associated with fewer sexual side effects and improved treatment adherence may be a viable option.
Brintellix®(vortioxetine) improved sexual dysfunction in most dimensions and phases unlike other antidepressants
CSFQ-14, Changes in Sexual Functioning Questionnaire; LS, Least squares; MMRM, mixed model for repeated measures.
Jacobsen PL et al. J Sex Med. 2015;12(10):2036–48.
Brintellix® is generally well tolerated
CSFQ-14, Changes in Sexual Functioning Questionnaire; LS, Least squares; MMRM, mixed model for repeated measures.
Jacobsen PL et al. J Sex Med. 2015;12(10):2036–48.
Brintellix® is generally well tolerated
* Based on unadjusted rates from product monographs, including Agomelatine (Valdoxan®) Summary of Product Characteristics.
2018; Vortioxetine (Brintellix®) Summary of Product Characteristics. 2019; Escitalopram (Cipralex®) Summary of Product
Characteristics. 2018; Citalopram (Cipramil®) Summary of Product Characteristics. 2018.
Adapted from: Kennedy SH et al. Can J Psychiatry 2016;61(9): 540–60.
Patients are significantly more satisfied with Brintellix® for treatment, as compared to the SNRI desvenlafaxine
In a double-blinded clinical trial of MDD patients, Brintellix® was superior to escitalopram in improving SSRI-induced treatment-emergent sexual dysfunction (TESD) in most dimensions and phases as assessed using the CSFQ-14 while efficacy measured with MADRS was maintained.3† In comparison to SNRIs, Brintellix® was found to be associated with fewer adverse events.4
* Based on unadjusted rates from product monographs, including Agomelatine (Valdoxan®) Summary of Product Characteristics.
2018; Vortioxetine (Brintellix®) Summary of Product Characteristics. 2019; Escitalopram (Cipralex®) Summary of Product
Characteristics. 2018; Citalopram (Cipramil®) Summary of Product Characteristics. 2018.
Adapted from: Kennedy SH et al. Can J Psychiatry 2016;61(9): 540–60.
Patients are significantly more satisfied with Brintellix® for treatment, as compared to the SNRI desvenlafaxine
In a double-blinded clinical trial of MDD patients, Brintellix® was superior to escitalopram in improving SSRI-induced treatment-emergent sexual dysfunction (TESD) in most dimensions and phases as assessed using the CSFQ-14 while efficacy measured with MADRS was maintained.3† In comparison to SNRIs, Brintellix® was found to be associated with fewer adverse events.4
†Defined as CGI-S 2. The CGI-S scale is a clinician-rated scale that can be used to assess a patient’s severity of symptoms as they relate to functioning before
and after initiating a study medication.
***p=0.034
McIntyre RS et al. Poster presented at ASCP. Poster W20. 2022.
When compared to the SNRI desvenlafaxine in particular, Brintellix® was associated with increased treatment adherence and satisfaction.5 With these advantages over SSRIs/SNRIs, Brintellix® is a viable option for a patient with partial response to an initial SSRI/SNRI treatment and suffering from associated sexual dysfunction.
†Defined as CGI-S 2. The CGI-S scale is a clinician-rated scale that can be used to assess a patient’s severity of symptoms as they relate to functioning before
and after initiating a study medication.
***p=0.034
McIntyre RS et al. Poster presented at ASCP. Poster W20. 2022.
When compared to the SNRI desvenlafaxine in particular, Brintellix® was associated with increased treatment adherence and satisfaction.5 With these advantages over SSRIs/SNRIs, Brintellix® is a viable option for a patient with partial response to an initial SSRI/SNRI treatment and suffering from associated sexual dysfunction.
†The study included well-treated patients with MDD who were in remission for depressive symptoms but were experiencing sexual
dysfunction while being treated with the SSRIs citalopram, sertraline or paroxetine.
Abbreviations:
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; MDD, major depressive disorder; MADRS, Montgomery-Åsberg Depression Rating Scale; CSFQ-14, Changes in Sexual Functioning Questionnaire Short Form; TESD, treatment-emergent sexual dysfunction
†The study included well-treated patients with MDD who were in remission for depressive symptoms but were experiencing sexual
dysfunction while being treated with the SSRIs citalopram, sertraline or paroxetine.
Abbreviations:
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin norepinephrine reuptake inhibitor; MDD, major depressive disorder; MADRS, Montgomery-Åsberg Depression Rating Scale; CSFQ-14, Changes in Sexual Functioning Questionnaire Short Form; TESD, treatment-emergent sexual dysfunction